Accepting graduate students


Research affiliations

Research summary

Dr. Kirk McManus’ cancer research program has two fundamental goals: 1) To identify the molecular determinants (abnormal genes, proteins and cellular pathways) driving cancer development and progression, with a particular focus on those impacting chromosome stability; and 2) To exploit these defective genes, proteins and pathways to develop highly personalized therapeutic strategies to better combat cancer.

A fundamental element of his cancer research program is to provide undergraduate, graduate and post-graduate trainees with innovative, comprehensive and unique training opportunities to enhance and advance their career options within various economic sectors including research, industry, biotech, health delivery, education and policy development.


Dr. Kirk McManus is a professor of biochemistry and medical genetics within the Rady Faculty of Health Sciences. He is also a senior scientist within the CancerCare Manitoba Research Institute at CancerCare Manitoba.

Dr. McManus received his bachelor of science in 1995 and master of science in 1999 from the University of Manitoba. In 1999, he moved to Edmonton, Alberta, to conduct his PhD studies in experimental oncology at the University of Alberta. He performed his post-doctoral work in molecular oncology at the Michael Smith Laboratories at the University of British Columbia and was subsequently recruited to CancerCare Manitoba and the University of Manitoba in June 2009.

His research interests are focused on identifying and characterizing the genes, proteins and pathways regulating chromosome stability in various cancer contexts and exploiting these defects to uncover novel therapeutic targets. He currently employs leading-edge genetics (RNAi and CRISPR/Cas9), biochemistry and cellular biology along with innovative quantitative imaging microscopy approaches and patient model systems to identify both genes and targets of interest. 

Dr. McManus has published extensively in cancer genetics with a particular focus on chromosome instability, drug target discovery and therapeutic targeting (synthetic lethality) in many cancer types, including colorectal and ovarian cancers.



  • Scientists’ Choice Award – Best Drug Discovery & Development Article of the Year (2016)
  • University of Manitoba Graduate Student Association Teaching Award (2016)
  • Merit Award for Research, Teaching and Service (2016)
  • Ken Hughes Young Investigator Award for Medical Research (2014)
  • Rh Award for Outstanding Contributions to Scholarship and Research in the Health Sciences (2014)
  • Canadian Institutes of Health Research/Manitoba Health Research Council – New Investigator Salary Award (2010-12)

ORCID profile

Visit Kirk McManus' ORCID profile for a complete listing, or find him on Google Scholar and ResearchGate.

Kirk McManus' profile

Contact us

Biochemistry and Medical Genetics
Room 336 Basic Medical Sciences Building
745 Bannatyne Avenue
University of Manitoba
Winnipeg, MB R3E 0J9 Canada